CompletedNot Applicable

Effect of Daily Consumption of Glycomacropeptide on Gut Microbiome and Blood Functional Proteome of Subjects With Irritable Bowel Syndrome

United States15 participantsStarted 2022-01-01

Plain-language summary

This study investigates the use of glycomacropeptide (GMP) as a means to manipulate the gut microbiome, metabolome and protein profile of subjects with irritable bowel syndrome (IBS).

Who can participate

Age range18 Years – 30 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Fluent in English * IBS diagnosis with Rome IV criteria * People who have a primary care provider Exclusion Criteria: * Lactose or milk protein intolerance * Any known other gastrointestinal disease or disorder beyond IBS, or major gastrointestinal surgery * Habitual use of laxatives or antacids * Pregnant or nursing. * Use of pre or probiotics within one month prior to the study * Use of antibiotics within one month prior to the study

What they're measuring

Measure the inflammatory markers in stool and blood using immunology multiplex assay

Timeframe: Baseline, GMP feeding week 1, 2 and 3 and post study without GMP feeding week 1, 2 and 3

Stool sample based gut microbiome composition using 16S rRNA gene sequencing

Timeframe: Baseline, GMP feeding week 1, 2 and 3 and post study without GMP feeding week 1, 2 and 3

Trial details

NCT IDNCT05482464

SponsorOregon State University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-09-01

View on ClinicalTrials.gov More Inflammatory Bowel Syndrome trials